Abstract:Interaction between gut microbiota, host immunity and metabolism has been suggested to crucially affect the development of insulin resistance (IR). This study aims to investigate how gut microbiota, inflammatory responses and metabolism in individuals with IR are affected by the supplementation of conjugated linoleic acid (CLA) and how this subsequently affects the pathophysiology of IR by using a high-fat diet-induced IR mouse model. Serum biochemical indices showed that 400 mg/kg body weight of CLA effectively attenuated hyperglycemia, hyperlipidemia, glucose intolerance and IR, while also promoting antioxidant capacities. Histomorphology, gene and protein expression analysis revealed that CLA reduced fat deposition and inflammation, and enhanced fatty acid oxidation, insulin signaling and glucose transport in adipose tissue or liver. Hepatic transcriptome analysis confirmed that CLA inhibited inflammatory signaling pathways and promoted insulin, PI3K-Akt and AMPK signaling pathways, as well as linoleic acid, arachidonic acid, arginine and proline metabolism. Gut microbiome analysis further revealed that these effects were highly associated with the enriched bacteria that showed positive correlation with the production of short-chain fatty acids (SCFAs), as well as the improved SCFAs production simultaneously. This study highlights the therapeutic actions of CLA on ameliorating IR via regulating microbiota–host metabolic and immunomodulatory interactions, which have important implications for IR control.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore whether conjugated linoleic acid (CLA) can improve insulin resistance (IR) caused by a high - fat diet by regulating the interaction between the gut microbiota and host metabolism and immune regulation. Specifically, the study aims to evaluate the effects of CLA supplementation on the gut microbiota, inflammatory response, and metabolism in a high - fat - diet - induced IR mouse model, and how these effects further influence the pathophysiology of IR. ### Research Background - **Obesity and Insulin Resistance**: The global obesity rate has more than tripled in the past two decades. Obesity is a key risk factor associated with multiple metabolic disorders, including insulin resistance. Insulin resistance is a clinical state in which the glucose uptake capacity of tissues such as the liver and adipose tissue is reduced due to the decreased biological effects of insulin, and is considered the main pathological mechanism in the progression of type 2 diabetes. - **The Role of the Gut Microbiota**: The gut microbiota and its metabolites play a crucial role in influencing host metabolism and immune function. A high - fat diet has been shown to change the gut microbiota, leading to a decrease in bacterial diversity, a reduction in beneficial bacteria, a change in the ratio of Firmicutes to Bacteroides, and an alteration in the short - chain fatty acids (SCFAs) profile. These changes can affect the immune environment of the gut, which in turn affects systemic inflammation and insulin resistance. ### Research Objectives - **The Potential Role of CLA**: Conjugated linoleic acid (CLA) is a mixture of fatty acids mainly found in dairy products and ruminant meat, and has multiple biological effects, such as anti - obesity and anti - inflammatory effects. Although the potential effects of CLA on regulating adipocyte function, lipid metabolism, and insulin sensitivity in humans have been reported, these effects remain controversial. - **Regulatory Mechanisms**: The study aims to explore whether CLA improves insulin resistance caused by obesity by regulating the interaction between the gut microbiota and host metabolism and immune regulation. Specifically, the study analyzed the changes in glucose tolerance, insulin sensitivity, lipid profile, inflammatory response, colonic microbial community, and metabolites in a high - fat - diet - induced IR mouse model with CLA supplementation. ### Main Findings - **Improvement of IR by CLA**: The study found that CLA at 400 mg/kg body weight effectively alleviated hyperglycemia, hyperlipidemia, glucose intolerance, and insulin resistance caused by a high - fat diet, and promoted antioxidant capacity. - **Metabolic and Immune Regulation**: CLA reduced fat deposition and inflammation, and enhanced fatty acid oxidation, insulin signaling, and glucose transport. - **Changes in the Gut Microbiota**: CLA supplementation significantly increased the abundance of bacteria positively correlated with short - chain fatty acid (SCFAs) production, while improving SCFAs production. - **Gene Expression and Signaling Pathways**: Liver transcriptome analysis showed that CLA inhibited inflammatory signaling pathways, and promoted insulin, PI3K - Akt, and AMPK signaling pathways, as well as linoleic acid, arachidonic acid, arginine, and proline metabolism. In conclusion, this study emphasizes the therapeutic potential of CLA to improve insulin resistance by regulating the interaction between the gut microbiota and host metabolism and immune regulation, which is of great significance for controlling insulin resistance.

Conjugated Linoleic Acid Ameliorates High Fat-Induced Insulin Resistance via Regulating Gut Microbiota–Host Metabolic and Immunomodulatory Interactions

Mixed conjugated linoleic acid sex-dependently reverses high-fat diet-induced insulin resistance via the gut-adipose axis

Conjugated Linoleic Acid Ameliorates Hepatic Steatosis by Modulating Intestinal Permeability and Gut Microbiota in Ob/ob Mice

Conjugated linoleic acid (CLA) reduces intestinal fatty acid uptake and chylomicron formation in HFD-fed mice associated with the inhibition of DHHC7-mediated CD36 palmitoylation and the downstream ERK pathway

Effects of Conjugated Linolenic Acid and Conjugated Linoleic Acid on Lipid Metabolism in Mice

Conjugated Linoleic Acid Supplementation under a High-Fat Diet Modulates Stomach Protein Expression and Intestinal Microbiota in Adult Mice

Conjugated linoleic acid (CLA) reduces HFD‐induced obesity by enhancing BAT thermogenesis and iWAT browning via the CD36–AMPK pathway

Combination of Fucoxanthin and Conjugated Linoleic Acid Attenuates Body Weight Gain and Improves Lipid Metabolism in High-Fat Diet-Induced Obese Rats.

Modulation Of Peroxisome Proliferator-Activated Receptor Gamma (Ppar Gamma) By Conjugated Fatty Acid In Obesity And Inflammatory Bowel Disease

Dietary conjugated linoleic acid and body composition

The effects of conjugated linoleic acid supplementation on glycemic control, adipokines, cytokines, malondialdehyde and liver function enzymes in patients at risk of cardiovascular disease: a GRADE-assessed systematic review and dose-response meta-analysis

The effect of conjugated linoleic acid supplementation in comparison with omega-6 and omega-9 on lipid profile: a graded, dose-response systematic review and meta-analysis of randomized controlled trials

Conjugated Linoleic Acid from Suaeda Salsa Improves the Intestinal Health in T2DM Mice by Regulating Colonic Barrier Function, Intestinal Glycolipid Transporters and Intestinal Flora

Ameliorating Inflammation in Insulin-resistant Rat Adipose Tissue with Abdominal Massage Regulates SIRT1/NF-κB Signaling

Conjugated linoleic acid: A potent fatty acid linked to animal and human health

A review on effects of conjugated linoleic fatty acid (CLA) upon body composition and energetic metabolism

10,12-Conjugated linoleic acid supplementation improves HDL composition and function in mice

Targeted inhibition of PPAR α ameliorates CLA ‐induced hypercholesterolemia via hepatic cholesterol biosynthesis reprogramming

The effect of conjugated linoleic acids on inflammation, oxidative stress, body composition and physical performance: a comprehensive review of putative molecular mechanisms

The effects of conjugated linoleic acid supplementation on anthropometrics and body composition indices in adults: a systematic review and dose-response meta-analysis

Allyl Isothiocyanate Ameliorates Lipid Accumulation and Inflammation in Nonalcoholic Fatty Liver Disease Via the Sirt1/AMPK and NF-κB Signaling Pathways.